Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.

about

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.

Item

http://www.wikidata.org/entity/Q47740661

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Erlotinib Plus Bevacizumab Pha ...... 5567): Updated Safety Results.

@en

Erlotinib Plus Bevacizumab Pha ...... ced Non-small-Cell Lung Cancer

@nl

type

Item

label

Erlotinib Plus Bevacizumab Pha ...... 5567): Updated Safety Results.

@en

Erlotinib Plus Bevacizumab Pha ...... ced Non-small-Cell Lung Cancer

@nl

prefLabel

Erlotinib Plus Bevacizumab Pha ...... 5567): Updated Safety Results.

@en

Erlotinib Plus Bevacizumab Pha ...... ced Non-small-Cell Lung Cancer

@nl

P1476

Erlotinib Plus Bevacizumab Pha ...... 5567): Updated Safety Results.

@en

P2093

Akihiro Seki

http://www.w3.org/2001/XMLSchema#string

Isamu Okamoto

http://www.w3.org/2001/XMLSchema#string

Koichi Goto

http://www.w3.org/2001/XMLSchema#string

Kosei Tajima

http://www.w3.org/2001/XMLSchema#string

Liang Tao

http://www.w3.org/2001/XMLSchema#string

Makoto Nishio

http://www.w3.org/2001/XMLSchema#string

Masahiko Shibata

http://www.w3.org/2001/XMLSchema#string

Noboru Yamamoto

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Yamamoto

http://www.w3.org/2001/XMLSchema#string

Takashi Seto

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.

P2888

s40264-017-0596-0

P304

229-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40264-017-0596-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29043496

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5808045

http://www.w3.org/2001/XMLSchema#string